Home Newsfeeds iRadimed Q3 EPS $0.45 Up From $0.23 YoY

iRadimed Q3 EPS $0.45 Up From $0.23 YoY

iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.45 per share. This is a 95.65 percent increase over earnings of $0.23 per share from the same period last year.

byBenzinga Newsdesk

July 29, 2022

1 minute read

iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.45 per share. This is a 95.65 percent increase over earnings of $0.23 per share from the same period last year.

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

By Benzinga Newsdesk

November 15, 8:02 AM

Chardan Capital analyst Keay Nakae maintains Better Therapeutics (NASDAQ:BTTX) with a Buy and lowers the price target from $17 to $14.

BTTX

Imperial Capital Initiates Coverage On Holley with Outperform Rating, Announces Price Target of $10

By Benzinga Newsdesk

August 9, 11:15 AM

Imperial Capital analyst Michael Piccolo initiates coverage on Holley (NYSE:HLLY) with a Outperform rating and announces Price Target of $10.

HLLY

PDS Biotech Announces Acceptance Of Abstract On Combination Of PDS0301 With Docetaxel In Metastatic Prostate Cancer For Oral Presentation By The National Cancer Institute At Cytokines 2023

By Benzinga Newsdesk

July 17, 8:05 AM

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary

PDSB